Artificial Intelligence & Machine Learning
,
Governance & Risk Management
,
Healthcare
Also: Embedded AI in Pharmaceutical Sector, the Story Behind Apple’s CEO Change
In this week’s panel, four ISMG editors examine what’s really behind Apple’s CEO transition, how pharmaceutical giants are racing to embed artificial intelligence across core operations, and why AI-driven threats are forcing a rethink of how quickly defenders can respond.
See Also: How Attackers Use AI to Outsmart Email Filters
The panelists – Chris Riotta, managing editor, GovInfoSecurity; Marianne Kolbasuk McGee, executive editor, HealthcareInfoSecurity; Michael Novinson, executive editor, ISMG Business; and Jennifer Lawinski, managing editor, CIO.inc – discussed:
- Apple’s leadership transition from long-time CEO Tim Cook to John Ternus and why the move appears less like a shakeup and more like a continuation of Apple’s hardware-first strategy – with no apparent plan to focus on AI-based solutions;
- How Merck’s multiyear deal with Google Cloud reflects a broader pharmaceutical sector push to deploy generative and agentic AI across research, manufacturing and commercial operations, as companies pursue faster drug development while grappling with data governance and regulatory risk;
- Why advances in AI are compressing the time between vulnerability discovery and exploitation to near real time, based on insights from Jeetu Patel, president and chief product officer at Cisco, and what that means for organizations moving toward AI-driven security operations to defend against machine-speed cyberthreats.
The ISMG Editors’ Panel runs weekly. Don’t miss our previous installments, including the April 8 edition on the implications of Anthropic’s AI bug finder and the April 17 edition on the looming onslaught of vulnerabilities discovered by Claude Mythos.

